AstraZeneca, Merck's star PARP inhibitor Lynparza expands reach in ovarian cancer with new US approval
Weeks after GSK widened the market for PARP inhibitor Zejula in patients with ovarian cancer, rival AstraZeneca’s market-leading Lynparza has also secured expanded use in women with the disease.
Lynparza, in combination with Roche’s Avastin, has been approved by the FDA for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who have experienced a complete or partial response to first-line platinum-based chemotherapy and whose disease is associated with homologous recombination deficiency (HRD) positive status, defined by either a BRCA mutation and/or genomic instability. Roughly one in two women with advanced ovarian cancer has an HRD+ tumor.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.